ABSTRACT
Single-agent cisplatin remains the golden standard in the treatment of advanced or recurrent cervical carcinoma. However, other combination regimens have resulted in increased response rates compared with single-agent cisplatin, but no increased overall survival (OS) has been shown in phase III randomized trials. Future therapy will have to investigate the role of immunotherapy, gene therapy, and cellular therapy possibly in combination with chemotherapy.
